Table 3 ROC Curve to Confirm Cyclin D1 Immunostaining Cutoff Threshold
Histology | |||||
|---|---|---|---|---|---|
 Immunolabelling cells | Percentage of Cyclin D1 immunolabelled tumor cells | ||||
Cut off (%) | AUC | p | Sensitivity (%) | Specificity (%) | |
 Carcinoma VS Adenoma/Background | 15.7 | 0.89 | <.0001* | 86.4 | 80.5 |
 Carcinoma/Adenoma VS Background | 5.8 | 0.93 | 0.003* | 94.4 | 92.3 |
 Immunolabelling cells | Percentage of Ki67 immunolabelled tumor cells | ||||
Cut off (%) | AUC | p | Sensitivity (%) | Specificity (%) | |
 Carcinoma VS Adenoma/Background | 3.5 | 0.58 | NS | 53.1 | 71.4 |
 Carcinoma/Adenoma VS Background | 5 | 0.54 | NS | 33.7 | 92.3 |
Cytology | |||||
 Immunolabelling cells | Percentage of Cyclin D1 immunolabelled tumor cells | ||||
Cut off (%) | AUC | p | Sensitivity (%) | Specificity (%) | |
 Malignant VS Adenoma/Background | 46 | 0.96 | <.0001* | 85 | 100 |